Home › Calculator › OMER Dividend Calculator 2026
OMER Dividend DRIP Calculator 2026
19.53% YieldHealthcareOmeros Corporation · NASDAQ
Price: $10.24 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When OMER pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your OMER snowball 📈
$10,000 in OMER → $59.5K in 10 years · $810.74/month
About Omeros Corporation (OMER) — Dividend Analysis 2026
Omeros Corporation is a biopharmaceutical firm with commercialized products, actively engaged in the discovery, development, and market introduction of both small-molecule and protein-based therapies, including treatments for rare diseases. The company's therapeutic endeavors primarily focus on inflammatory conditions, illnesses mediated by the complement system, cancers linked to immune system dysregulation, and disorders characterized by addiction or compulsion. Its robust clinical pipeline features several promising candidates. Narsoplimab (also known as OMS721 or MASP-2), a leading asset, has successfully concluded pivotal trials for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA). This drug is also currently undergoing Phase III clinical evaluation for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS), in addition to a Phase II trial investigating its potential for treating COVID-19. Further expanding its clinical portfolio, Omeros is developing PPAR? (OMS405) in Phase II for opioid and nicotine dependence. PDE7 (OMS527) is progressing through Phase I studies for addiction, compulsive disorders, and movement disorders. Additionally, MASP-3 (OMS906) is currently in Phase I trials for paroxysmal nocturnal hemoglobinuria (PNH) and other conditions involving the alternative complement pathway. Beyond its clinical efforts, the company maintains a dynamic preclinical program. This includes small-molecule inhibitors targeting MASP-2, which are being explored for applications in aHUS, IgAN, HSCT-TMA, and age-related macular degeneration. Also in development is a next-generation, longer-acting antibody that targets MASP-2, alongside MASP-3 small-molecule inhibitors designed to address PNH and other alternative pathway disorders. Omeros's preclinical research further encompasses GPR174 inhibitors, as well as Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various oncological indications. The company is also investigating G protein-coupled receptor targets for a broad spectrum of diseases, including immunological, immuno-oncological, metabolic, central nervous system (CNS), cardiovascular, musculoskeletal, and other conditions. Established in 1994, Omeros Corporation is headquartered in Seattle, Washington.
Compare OMER with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full OMER DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open OMER position with:
🌍 OMER Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold OMER.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 19.53% | 16.73% | $1,953 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 16.60% | 13.80% | $1,660 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 15.62% | 12.82% | $1,562 / yr |
| 🇬🇧 UK ISA | 0% | 19.53% | 16.73% | $1,953 / yr |
| 🇬🇧 UK Taxable | 8.75% | 17.82% | 15.02% | $1,782 / yr |
| 🇨🇦 TFSA | 0% | 19.53% | 16.73% | $1,953 / yr |
| 🇨🇦 CA Taxable | 25% | 14.65% | 11.85% | $1,465 / yr |
| 🇦🇺 Super (pension) | 15% | 16.60% | 13.80% | $1,660 / yr |
| 🇦🇺 AU Taxable | 30% | 13.67% | 10.87% | $1,367 / yr |
| 🇩🇪 DE Taxable | 26.375% | 14.38% | 11.58% | $1,438 / yr |
| 🇫🇷 FR Taxable | 30% | 13.67% | 10.87% | $1,367 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 OMER Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 OMER Dividend Payment Schedule
OMER pays quarterly — 4 times per year. Next ex-div: TBD.
📊 OMER vs Healthcare Benchmarks
How OMER compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for OMER sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ OMER Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2026-07-22 | 1,000,000 | $9.84 | $9.84M | ||
| A-Award | 2026-07-22 | 105,000 | $9.84 | $1.03M | ||
| A-Award | 2026-07-22 | 105,000 | $9.84 | $1.03M | ||
| A-Award | 2026-06-18 | 15,000 | $10.28 | $154.2K | ||
| A-Award | 2026-06-18 | 15,000 | $10.28 | $154.2K | ||
| A-Award | 2026-06-18 | 15,000 | $10.28 | $154.2K | ||
| A-Award | 2026-06-18 | 15,000 | $10.28 | $154.2K | ||
| A-Award | 2026-06-18 | 15,000 | $10.28 | $154.2K | ||
| A-Award | 2026-06-18 | 15,000 | $10.28 | $154.2K | ||
| A-Award | 2026-06-18 | 15,000 | $10.28 | $154.2K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the OMER dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Omeros Corporation (OMER) is currently trading at $10.24, 50% below its 52-week high. The current dividend yield is 19.53% based on an annual payout of $2.00 per share.
OMER (Omeros Corporation) — 19.53% Dividend Yield Analysis
Omeros Corporation (OMER) is a healthcare stock currently trading at $10.24 with a dividend yield of 19.53%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (19.53%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.